Article, 2024

Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes

Journal of the European Academy of Dermatology and Venereology, ISSN 1468-3083, 0926-9959, Volume 38, 7, Pages 1251-1280, 10.1111/jdv.19912

Contributors

Knobler, Robert Martin 0000-0002-7380-7062 (Corresponding author) [1] Geroldinger-Simic, Marija [2] [3] Kreuter, Alexander 0000-0003-2275-499X [4] Hunzelmann, N. [5] Moinzadeh, P. [5] Rongioletti, Franco 0000-0002-2227-581X [6] Denton, Christopher Paul 0000-0003-3975-8938 [7] Mouthon, Luc [8] [9] Cutolo, Maurizio [10] Smith, Vanessa 0000-0001-6271-7945 [11] [12] [13] Gabrielli, Armando [14] Bagot, Martine [15] Olesen, A. B. [16] Foeldvari, Ivan 0000-0003-0659-5298 [17] Jalili, Ahmad [18] Kähäri, Veli-Matti 0000-0003-2421-9368 [19] Kárpáti, Sarolta K 0000-0002-8472-0712 [20] Kofoed, K. [21] Olszewska, M. [22] Panelius, Jaana [23] Quaglino, P. [24] Seneschal, Julien 0000-0003-1139-0908 [25] Sticherling, M. [26] Sunderkötter, Cord H 0000-0002-2929-145X [27] Tanew, Adrian 0000-0002-4433-2790 [28] Wolf, P. [29] Worm, Margitta [30] Skrok, Anna [22] Rudnicka, L. [22] Krieg, Thomas [5]

Affiliations

  1. [1] Medical University of Vienna
    2. [NORA names: Austria; Europe, EU; OECD];
  2. [2] Department of Dermatology, Ordensklinikum Linz Elisabethinen, Linz, Austria
    3. [NORA names: Austria; Europe, EU; OECD];
  3. [3] Johannes Kepler University of Linz
    4. [NORA names: Austria; Europe, EU; OECD];
  4. [4] Helios St. Elisabeth Klinik Oberhausen
    5. [NORA names: Germany; Europe, EU; OECD];
  5. [5] University of Cologne
    6. [NORA names: Germany; Europe, EU; OECD];

Abstract

The term 'sclerosing diseases of the skin' comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present consensus provides an update to the 2017 European Dermatology Forum Guidelines, focusing on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, updated strategies for the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 1 of this consensus provides clinicians with an overview of the diagnosis and treatment of localized scleroderma (morphea), and systemic sclerosis including overlap syndromes.

Keywords

European, European Dermatology Forum guidelines, First, autoantibodies, changes, clinical subtypes, clinicians, consensus, consensus statement, dermatologic entities, diagnosis, diagnostic score, differential diagnosis, disease, entities, extracutaneous involvement, features, fibrotic changes, guidelines, histopathological features, involvement, localized scleroderma, morphea, overlap, overlap syndrome, overview, scleroderma, sclerosing, sclerosing disease, sclerosing skin diseases, sclerosis, scores, serum, serum autoantibodies, skin, skin diseases, statements, subtypes, syndrome, systemic sclerosis, treatment, treatment of localized scleroderma, update

Funders

  • GlaxoSmithKline (United Kingdom)
  • Mallinckrodt (United States)
  • Research Foundation - Flanders
  • AstraZeneca (United Kingdom)
  • Fund for Scientific Research

Data Provider: Digital Science

LINKS
-

Matching Records in NORA

SUBJECTS
+

METRICS
+